Background -Pulmonary artery pressure is elevated in patients with advanced chronic obstructive pulmonary disease (COPD). Release of atrial natriuretic peptide (ANP) is increased in pulmonary hypertension and this hormone may both selectively vasodilate pulmonary vessels and inhibit pulmonary vascular remodelling. The hypothesis that ANP has a physiological role in protection of the pulmonary circulation from pressure overload, and that it may be beneficial in patients with COPD, has been examined. Methods -Ten patients with hypoxic COPD were infused for 30 minute periods with saline followed by ANP at 0-4, 2, and 10 pmol/kg/min respectively via a pulmonary artery catheter whilst monitoring haemodynamics and oxygenation. Results -Levels of immunoreactive ANP (irANP) increased from a mean (SD) of 23 (15) pmol/l to a maximum of 94 (41) pmol/l. Neither systemic blood pressure, cardiac output nor total systemic vascular resistance showed any correlation with irANP levels. There were negative correlations between levels of ANP and mean pulmonary artery pressure which fell from 28-7 to 25 9 mm Hg, pulmonary artery wedge pressure which fell from 6 5 to 4-6 mm Hg, and total pulmonary vascular resistance which fell from 489 to 428 dynes s cm -5. There was a small fall in Paco2 from 6-2 to 5-9 kPa, whilst venous admixture and oxygen delivery both increased non-significantly. Conclusions -At these pathophysiological concentrations there was evidence that ANP selectively reduced right ventricular afterload. These data support the hypotheses that increased plasma levels of ANP may be beneficial in hypoxic COPD, and that endogenous ANP may ameliorate pulmonary hypertension in humans. (Thorax 1994;49:233-239) Pulmonary vascular resistance is elevated in patients with advanced chronic obstructive pulmonary disease (COPD)l associated with a progressive vascular remodelling of small pulmonary arteries and arterioles,2 although many other factors also contribute. As a result of increased afterload on the right ventricle, stroke volume and ejection fraction are depressed; cardiac output is maintained by a relative tachycardia.3 Oedema occurs during episodes of acute-on-chronic respiratory failure, a syndrome commonly known as "hypoxic cor pulmonale." This is an important step in the natural history of the disease: without treatment 65% of patients die within five years of the first episode.4
Pulmonary vascular resistance is elevated in patients with advanced chronic obstructive pulmonary disease (COPD)l associated with a progressive vascular remodelling of small pulmonary arteries and arterioles,2 although many other factors also contribute. As a result of increased afterload on the right ventricle, stroke volume and ejection fraction are depressed; cardiac output is maintained by a relative tachycardia.3 Oedema occurs during episodes of acute-on-chronic respiratory failure, a syndrome commonly known as "hypoxic cor pulmonale." This is an important step in the natural history of the disease: without treatment 65% of patients die within five years of the first episode. 4 The role of vasodilators is controversial.56 There have been several short and medium term trials of vasodilator treatment in the condition,7-'2 reviewed by Howard.5 Effects on arterial blood gases and cardiac output have been variable. Most agents have caused greater reduction of systemic than pulmonary vascular resistance. Some longer term trials have found that the pulmonary hypotensive effect disappeared with time, whilst others have found continued benefit at one year. No effect on prognosis has yet been shown.
There are three lines of evidence to suggest that atrial natriuretic peptide (ANP) may be helpful in patients with advanced COPD. Firstly, numerous studies in intact animals,'3'5 in animal isolated lung preparations,6 17 and in isolated animal' 120 and human vessels2' 22 have suggested that the vasodilator activity of ANP may be selective for the pulmonary vascular bed. Secondly, there is evidence that ANP can inhibit vascular remodelling, both in vitro23 and in the rat model of hypoxic pulmonary hypertension.2s26 This has been achieved both by chronic infusion of ANP24 and by the inhibition of ANP metabolism with neutral endopeptidase inhibitors.2526 Thirdly, the well known diuretic and natriuretic effects of ANP27 may have a value in reversing the episodic fluid retention. Against these possible benefits is the potential disadvantage that, by acutely antagonising hypoxic pulmonary vasoconstriction, ANP may impair ventilationperfusion matching and exacerbate hypoxia.
In this study we have examined the response of patients with hypoxic COPD to levels of ANP seen in severe pulmonary hypertension. Physiological release was simulated by infusing ANP into the main pulmonary artery in 10 subjects. The hypotheses to be tested were (1) that these levels of ANP, achievable by pharmacological modification of ANP metabolism,28 have a beneficial effect on pulmonary haemodynamics in COPD; and (2) that ANP has a specific effect on the pulmonary vasculature. Finding the hypotheses to be correct would suggest that inhibitors of ANP metabolism may be of therapeutic use in COPD, and that the high concentrations of ANP found in severe pulmonary hypertension may have a homeostatic function.
Methods

PATIENTS
Local ethical committee approval for the study was obtained. A power calculation showed that, to allow an 80% chance of detecting a fall in pulmonary artery pressure (PPA) of 5 mmHg by a two tailed paired t test with a = 0 05, assuming a variance of the difference between pairs of 28 (from Adnot et al '9) , at least nine patients would be required. Ten patients were therefore enrolled, selected from a respiratory outpatient clinic and included after giving formal written consent.
Inclusion criteria
Patients were included in the study if they satisfied all the following conditions: severe chronic airflow obstruction with FEV,/FVC less than 60%; history of more than 10 pack years of tobacco consumption; stable respiratory failure with Pao2 < 8-0 kPa.
Exclusion criteria
Patients were excluded if they had any clinical evidence of ischaemic or valvular heart disease, any significant intercurrent disease, or had had an acute exacerbation of COPD during the three months before the study. Because ANP is known to cause an increase in haematocrit as a result of a shift of fluid from the intravascular space, any patient with a haematocrit of > 50% was also to have been excluded, although no otherwise eligible subject was excluded on the basis of this criterion.
STUDY PROTOCOL
Patients were seen by a dietician to establish a constant salt intake over the week before the study day, and were admitted to hospital either on the evening before or the morning of the study. On rising patients were asked to micturate. They were not given oxygen supplementation or diuretic treatment on the day of the study, but were allowed other morning medication and a light breakfast. They then remained nil by mouth until completion of the study. Just before commencement of the study patients were again asked to void the bladder, storing an aliquot of urine at -20°C.
Right heart catheterisation was performed in an operating theatre under sterile conditions. A 7 French gauge, five lumen, flow directed, balloon tipped, thermodilution catheter (Criticath, Spectramed Inc) was introduced through a brachial or internal jugular vein. Placement of the catheter tip in the pulmonary artery was determined by monitoring the pressure trace during advancement, if necessary with the aid of an image intensifier.
The catheter was clamped in the position at which a pulmonary artery wedge pressure could be recorded. After catheter insertion patients sat semirecumbent for the duration of the study.
A 21-gauge intravenous cannula (Viggo) was positioned in a forearm vein for peripheral venous blood samples. Transcutaneous oxygen saturation (Sao2) and pulse rate were continuously monitored with a pulse oximeter (Minolta Pulsox-7). Systemic blood pressure was measured with a Dynamap sphygmomanometer on the contralateral arm. Cardiac output measurements were made in triplicate, each thermal bolus consisting of 10 ml of room temperature saline. Cardiac output was determined with a Gould Model SP2009B recorder and bedside computer. Arterial blood gas samples were taken from the radial artery during the baseline saline infusion and maximal ANP infusion.
ANP INFUSION
There were four infusion periods, each lasting 30 minutes. For the first period saline was infused at the same rate as that required for the maximum dose of ANP. Incremental doses of ANP were then infused, equivalent to 0 4, 2, and 10pmol/kg/min (called ANP-1, ANP-2, and ANP-3, respectively). We have previously shown that these doses produce plasma levels within the pathophysiological range and have renal effects when infused into normal volunteers. 30 The following measurements were taken after 15 minutes of each infusion period: pulmonary artery pressure, cardiac output, pulse rate, systemic blood pressure, arterial oxygen saturation (Sao2), and mixed venous blood gas tensions. Venous blood samples were taken from the peripheral venous cannula for immediate centrifugation and were stored at -20°C for subsequent assay of plasma ANP concentration. Fifteen minutes after the end of the final infusion of ANP a further set of recordings was made and urine collected and stored at -20°C.
MATERIALS
Human synthetic ANP (Sigma Chemical Company, Poole, Dorset) was dissolved in 0-05 mol/l acetic acid (FSA Laboratory Supplies, Loughborough) and sterilised by passage through a Millex GV, low protein binding filter (Millipore, Harrow, Middlesex), the first 1-0 ml being discarded. It was then diluted to 2 nmol/ml in a solution of 50% normal saline (Baxter, Thetford) and 50% Haemaccel (Hoechst, Hounslow, Middlesex) to minimise adsorption of ANP to surfaces. Vials containing 15 ml of the solution were frozen at -20°C until used.
Before infusion ANP was thawed and diluted to 0 5 pmol/l with normal saline. The solution was infused in a syringe driver (Vickers) via the "CVP medication" lumen of the pulmonary artery catheter. Patient 5 also had evidence of fibrotic lung disease.
sufficiently severe hypoxaemia to qualify (nos 3 and 9) having a Pao2 greater than 73 kPa.
Five patients had a history of oedema, although none was in overt cor pulmonale during the study.
PLASMA ANP LEVELS
As can be seen in fig 1 there was a dose dependent increase in serum levels of irANP (ANOVA p< 1 x 10-13). Both of the higher rates of ANP infusion (ANP-2 and ANP-3) resulted in significant increases, by 89% (p < 0 005) and 422% (p < 00005) of baseline values, respectively. One patient (no. 4) showed an atypical response. The resting ANP level was the highest for the group at 50 pmol/l, and levels were not increased by subsequent ANP infusion. This subject also had the highest resting mean PPA at 37 mm Hg and was the only subject whose PPA did not fall during ANP infusion; indeed it rose to 40 mmHg. He experienced a fall in Pao2 during ANP-3 from 6-6 to 6-1 kPa, and Paco2 fell from 7-0 to 6-6 kPa.
HAEMODYNAMIC EFFECTS
Pulmonary haemodynamics Haemodynamic effects of ANP infusion are shown in table 2. The baseline mean pulmonary artery pressure and total pulmonary vascular resistance were elevated in all patients (ranges 20-38 mm Hg and 292-740 dynes s cm-5, respectively). Mean pulmonary artery pressure showed a significant, negative correlation with irANP levels, falling from a mean (SD) of 28 7 (6 4) mm Hg during saline infusion to 25-9 (6-9) mm Hg at maximum infusion rate (r = -055, p < 0-005; figs 2 and 3). Total pulmonary vascular resistance was also significantly correlated, with a fall of 12% from 489 (168) to 428 (151) dynes s cm-I (r= -0-46, p < 0 005; fig 4) . There was no correlation with pulmonary arteriolar resistance which fell from 329 (125) to 299 (96)dynesscm 5(r= -0-11, p=04; table 2). resistance, nor systemic blood pressure correlated with irANP levels (table 2). Total systemic vascular resistance fell by 5% from 1887 dynes s cm-5 during saline infusion to 1799 dynes s cm-5 at ANP-3 (r =-007, p = 0 98). In four patients the PPAW was unobtainable, but none of the remaining patients had an elevated resting value (range 5 2-9 mm Hg). There was a significant correlation between ANP levels and pulmonary artery wedge pressure, which fell from 6-5 (1 1) to 4.6 (1 4) mm Hg at the maximum dose (r = -080, p<0001; fig 5) . Furthermore, PPAW was strongly correlated with both PPA (r=0-67, p < 001) and TPVR (r = 0-60, p < 0-01) in the six subjects in whom it was measured.
Systemic haemodynamics Neither cardiac index, total systemic vascular
GAS EXCHANGE
There was a small but significant fall in Paco2 from 6-2 (0 9) to 5-9 (0 9) kPa, p < 0-0005 (table  2) . The mean Pao2 showed no significant change from 6 7 (0 8)kPa at baseline to 6-9 (0-9) kPa at ANP-3. Individual patients varied in their response: in five patients Pao2 increased by a mean of 0-6 (range + 0 3 to + 0 8) kPa, and in five patients it fell by a mean of -0 4 (range -0 2 to -0 6) kPa. The oxygen saturation measured by pulse oximetry suggested a significant, positive correlation between ANP levels and Sao2 (r = 0 42, p<0-01).
To determine the right to left shunt fraction, mixed venous blood gases were assessed in nine patients. As might be expected shunt fraction, which is partly derived from Pao2, also showed a variable response to ANP infusion between patients, increasing in five and falling in four.
RENAL EFFECTS
Urinary volume was not assessed. However, creatinine concentration fell from 9-3 (3-9) to 5.9 (3 6) mmol/l (p < 0-02), and the ratio of urinary sodium to creatinine rose from 12 (1 1) to 22 (12) (p < 0 002).
ADVERSE EFFECTS
The ANP infusion was well tolerated. No patient required supplemental oxygen during the procedure. One patient felt transiently faint upon removal of the right heart catheter, associated with systemic hypotension. This resolved within three minutes and was typical of a vasovagal episode.
Discussion
As expected, all patients had evidence of a restricted pulmonary vascular bed with raised mean pulmonary artery pressures, total pulmonary vascular resistance and, in the six in whom it could be measured, elevated pulmonary arteriolar resistance. The normal PPAW measurements and normal cardiac index suggest that the left ventricular function of the group was unimpaired.
As we have previously found,3" mean (SD) (10) 82 (9) 86 (12) 89 (12) 87 ( 
ANP-2
Infusion period ANP-3 Recovery baseline serum irANP levels were mildly elevated at 23 (15) pmol/l compared with the levels of less than 12 pmol/l found by our assay in normal subjects. Infusion of ANP was associated with a dose related increase in plasma irANP levels up to concentrations previously found in patients with severe pulmonary hypertension. 34 The primary endpoint of this study was to establish the effect of such pathophysiological levels of ANP on the pulmonary circulation in COPD. The observed fall in mean pulmonary artery pressure was modest, but correlated significantly with ANP levels.
Our patients also showed a renal response to ANP as shown by the significant increase in urinary sodium to creatinine ratio, similar to that we have previously described in normal volunteers. 30 The reduction in TPVR was a result of the pulmonary artery pressure falling in the presence of a stable cardiac output. The reduction of right ventricular afterload appears to have been due in large part to the fall in PPAW, accounting for approximately 36% of the reduction in TPVR in the subjects in whom it was measurable. Indeed, a fall in PPAW has been a consistent finding when ANP has been infused variously into animals, normal human volunteers,35 and patients with heart failure.'$38
Pulmonary arteriolar resistance, representing the degree of vasoconstriction present in the pulmonary vascular bed, did not change significantly in the patients in whom it could be calculated. The data do not allow conclusions to be drawn on whether pulmonary vasodilatation occurred at these levels of irANP, and whether this mechanism contributed to the fall in right ventricular afterload.
Caution should be exercised in interpreting the significance of changes in the multiple secondary and derived endpoints examined in this study. However, there was little evidence for effects of the infusion on systemic haemodynamics, with the exception of PPAW and heart rate. ANP infusion was not associated with changes in systemic arterial pressure with or in total systemic vascular resistance (TSVR). TSVR is the result of both the pres- One other study has examined the effect of ANP infusion in human pulmonary hypertension. Adnot et aP29 infused incremental doses of ANP over 10 minute periods via a peripheral vein in a group of seven patients with hypoxic COPD. They achieved much higher peripheral blood irANP levels than in our study, with even the lowest dose increasing the concentration from a baseline value of 44 pmol/l up to 120 pmol/l. These higher plasma concentrations had a significant depressor effect on the systemic circulation. These authors also '-3 Recovery found evidence of pulmonary selectivity, however, with a much greater fall in pulmonary than systemic vascular resistance. As in our ring different infusion study they also found a fall in Paco2, apparently due to an increase in minute ventilation. Despite this, and in contrast to our study, Pao2 ;temic circulation and fell sharply and significantly; we agree with :ause right atrial pres-their conclusion that this was due to the more infusion,39 the lack of profound pulmonary vasodilatation they r suggests that relax-observed exacerbating ventilation-perfusion systemic resistance mismatching. Several studies have shown that ANP levels small but significant are elevated in pulmonary hypertension, nting for cardiac out-whether due to various lung diseases3441 42 or to in the face of the cardiac failure. 43 In this study we have found l. The lack of an in-evidence that the concentrations of ANP found has also been found in in severe pulmonary hypertension may selectand normal human ively reduce right ventricular afterload in aguishes ANP from patients with hypoxic COPD. Thus a negative likely explanation is feedback loop may exist in which ANP release tion in cardiac preload is increased to ameliorate the harmful effects of asodilator.
pulmonary hypertension on the pulmonary *y vascular resistance vasculature and right heart. The beneficial mean arterial oxygen acute effects of low dose ANP suggest that ignificant increase in drugs which inhibit its metabolism may have ) patient developed therapeutic potential in COPD. 
